The Current Challenge of Immune Globulin Access
Understanding the factors contributing to the current shortage of immune globulin could help to address a crisis that threatens dire consequences for patients.
High Oncotic Pressure Cardiopulmonary Bypass Priming with Human Albumin Improves Outcomes in Pediatric Open-Heart Surgery
Specialists at India’s Sir Ganga Ram Hospital conducted a double-blinded, randomized controlled study to examine the impact of high oncotic pressure priming by the addition of 20 percent human albumin prior to the initiation of CPB
First-Line Intravenous Immune Globulin Monotherapy Evaluated in Idiopathic Inflammatory Myopathy
The investigators concluded first-line IVIG monotherapy led to clinically relevant improvement in nearly one-half of IIM patients, the majority of whom experienced a rapid clinical response.
Predictive Medicine: How DNA Testing Is Influencing Healthcare
Will genetic testing and whole genome sequencing become part of the standard of care in treating patients?
Live Donor Organ Transplant: A Physician’s Perspective
Nancy Ascher, MD, PhD, has devoted her career to organ transplantation and transplant surgery.
Anti-COVID Monoclonal Cocktails
Newly created treatments for high-risk COVID-19 patients have proved highly effective. Unfortunately, challenges with their distribution and administration have limited their use.
Hemophilia Gene Therapy: Cures May Finally Be at Hand
The decades-old dream is to correct the factor deficiency through a single infusion of a hemophilia gene therapy that produces steady high protective levels of FVIII or FIX.
Subcutaneous Immune Globulin May Be a Treatment Option in Stiff Person Syndrome Patients Intolerant to Intravenous Immune Globulin
SCIG may be a reasonable and safe alternative for SPS patients who do not tolerate IVIG, with the caveat that allergic and injection site reactions can be a limiting factor for some patients.
Low Rate of Inhibitor Development in Previously Untreated Hemophilia A Patients Managed with Simoctocog Alfa (Nuwiq)
The investigators concluded PUPs treated with simoctocog alfa had a lower high-titer inhibitor rate than PUPs initially treated with hamster-cell-derived recombinant FVIII products.
Against the Storm: High-Dose IVIG as an Immunoregulatory Treatment Strategy for Severe COVID-19
While there may be no “magic bullet” to treat cytokine storm, one widely used immunomodulatory agent in particular — polyclonal intravenous immune globulin (IVIG) purified from healthy donor plasma — is distinguished by the simple fact that it is anything but a narrowly targeted treatment.
